Insulin/IGF Axis in Breast Cancer: Clinical Evidence and Translational Insights.
BMI
IGF
breast cancer
host metabolism
insulin resistance
Journal
Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414
Informations de publication
Date de publication:
19 01 2021
19 01 2021
Historique:
received:
29
12
2020
revised:
17
01
2021
accepted:
18
01
2021
entrez:
22
1
2021
pubmed:
23
1
2021
medline:
24
6
2021
Statut:
epublish
Résumé
Breast cancer (BC) is the most common neoplasm in women. Many clinical and preclinical studies investigated the possible relationship between host metabolism and BC. Significant differences among BC subtypes have been reported for glucose metabolism. Insulin can promote tumorigenesis through a direct effect on epithelial tissues or indirectly by affecting the levels of other modulators, such as the insulin-like growth factor (IGF) family of receptors, sex hormones, and adipokines. The potential anti-cancer activity of metformin is based on two principal effects: first, its capacity for lowering circulating insulin levels with indirect endocrine effects that may impact on tumor cell proliferation; second, its direct influence on many pro-cancer signaling pathways that are key drivers of BC aggressiveness. In the present review, the interaction between BC, host metabolism, and patients' prognosis has been reviewed across available literature evidence. Obesity, metabolic syndrome, and insulin resistance are all involved in BC growth and could have a relevant impact on prognosis. All these factors act through a pro-inflammatory state, mediated by cytokines originated in fat tissue, and seem to be related to a higher risk of BC development and worse prognosis.
Sections du résumé
BACKGROUND
Breast cancer (BC) is the most common neoplasm in women. Many clinical and preclinical studies investigated the possible relationship between host metabolism and BC. Significant differences among BC subtypes have been reported for glucose metabolism. Insulin can promote tumorigenesis through a direct effect on epithelial tissues or indirectly by affecting the levels of other modulators, such as the insulin-like growth factor (IGF) family of receptors, sex hormones, and adipokines. The potential anti-cancer activity of metformin is based on two principal effects: first, its capacity for lowering circulating insulin levels with indirect endocrine effects that may impact on tumor cell proliferation; second, its direct influence on many pro-cancer signaling pathways that are key drivers of BC aggressiveness.
METHODS
In the present review, the interaction between BC, host metabolism, and patients' prognosis has been reviewed across available literature evidence.
CONCLUSIONS
Obesity, metabolic syndrome, and insulin resistance are all involved in BC growth and could have a relevant impact on prognosis. All these factors act through a pro-inflammatory state, mediated by cytokines originated in fat tissue, and seem to be related to a higher risk of BC development and worse prognosis.
Identifiants
pubmed: 33477996
pii: biom11010125
doi: 10.3390/biom11010125
pmc: PMC7835955
pii:
doi:
Substances chimiques
Insulin
0
Somatomedins
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
Int J Cancer. 2007 Aug 15;121(4):856-62
pubmed: 17397032
PLoS One. 2012;7(5):e36497
pubmed: 22662119
Lancet. 2009 Nov 14;374(9702):1677-86
pubmed: 19878986
JAMA Oncol. 2019 Feb 1;5(2):155-163
pubmed: 30520976
Neoplasia. 2011 Jun;13(6):504-15
pubmed: 21677874
Curr Surg Rep. 2016 Apr;4:
pubmed: 29623246
PLoS One. 2011;6(11):e27694
pubmed: 22096613
Gynecol Endocrinol. 2013 Mar;29(3):263-7
pubmed: 23174088
J Clin Invest. 1990 Nov;86(5):1503-10
pubmed: 2243127
Breast Cancer Res Treat. 2011 Aug;128(3):783-94
pubmed: 21655990
Diabetologia. 2009 Jan;52(1):17-30
pubmed: 18941734
Front Endocrinol (Lausanne). 2020 Feb 20;11:58
pubmed: 32153503
Cell Mol Immunol. 2020 Oct 19;:
pubmed: 33077904
Medicine (Baltimore). 2016 Mar;95(9):e2825
pubmed: 26945364
Nat Rev Cancer. 2008 Dec;8(12):915-28
pubmed: 19029956
Breast Cancer Res. 2015 Aug 19;17:112
pubmed: 26286584
Ann Oncol. 2014 Oct;25(10):1901-1914
pubmed: 24769692
Br J Cancer. 2013 Nov 26;109(11):2792-7
pubmed: 24157825
Breast Cancer Res Treat. 2008 May;109(1):123-39
pubmed: 17578664
J Clin Oncol. 2012 Jul 20;30(21):2593-600
pubmed: 22564993
JAMA Oncol. 2018 Nov 1;4(11):e181771
pubmed: 29931120
Curr Cancer Drug Targets. 2015;15(8):665-83
pubmed: 26452383
J Natl Cancer Inst. 2009 Jan 7;101(1):48-60
pubmed: 19116382
Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):701-5
pubmed: 19240238
Semin Oncol. 2016 Feb;43(1):123-133
pubmed: 26970131
Sci Rep. 2020 Feb 4;10(1):1804
pubmed: 32019974
Endocr Rev. 2009 Oct;30(6):586-623
pubmed: 19752219
Cancer Res. 2008 Oct 15;68(20):8322-32
pubmed: 18922904
Clin Cancer Res. 2010 Mar 15;16(6):1695-700
pubmed: 20215559
Breast Cancer Res Treat. 2011 Nov;130(2):587-97
pubmed: 21667121
Sci Rep. 2018 Oct 18;8(1):15454
pubmed: 30337563
Cancer Epidemiol Biomarkers Prev. 2017 Dec;26(12):1730-1735
pubmed: 28939589
J Clin Oncol. 2005 Mar 1;23(7):1370-8
pubmed: 15684320
Mol Cancer. 2016 Jan 22;15:8
pubmed: 26801096
Breast Cancer Res Treat. 2016 Aug;159(1):79-86
pubmed: 27460638
World J Surg Oncol. 2020 Sep 9;18(1):242
pubmed: 32907593
J Clin Oncol. 2011 Jan 1;29(1):32-9
pubmed: 21115858
Cell. 2003 Nov 26;115(5):577-90
pubmed: 14651849
Am J Epidemiol. 2000 Sep 15;152(6):514-27
pubmed: 10997541
Novartis Found Symp. 2004;262:3-9; discussion 9-18, 265-8
pubmed: 15562820
Lancet Oncol. 2010 Jun;11(6):530-42
pubmed: 20472501
Front Oncol. 2012 Oct 04;2:123
pubmed: 23061041
J Womens Health. 1997 Feb;6(1):49-62
pubmed: 9065374
Histopathology. 2012 Oct;61(4):652-9
pubmed: 22759273
Cancer Prev Res (Phila). 2014 Sep;7(9):867-85
pubmed: 24985407
Breast Cancer Res Treat. 2013 Apr;138(3):657-64
pubmed: 23532539
Breast Cancer Res Treat. 2010 Jun;121(2):479-83
pubmed: 19851862
Cell Stress. 2019 Jul 01;3(9):284-294
pubmed: 31535085
Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):2009-14
pubmed: 16103453
Clin Cancer Res. 2007 Jun 15;13(12):3611-6
pubmed: 17575225
Clin Cancer Res. 2018 Oct 15;24(20):5165-5177
pubmed: 29941485
Breast Cancer Res Treat. 2020 May;181(1):61-68
pubmed: 32200486
Mol Oncol. 2018 Jan;12(1):21-32
pubmed: 28766847
Ann Intern Med. 1990 Feb 1;112(3):182-6
pubmed: 2297194
PLoS One. 2013;8(2):e56836
pubmed: 23418605
J Natl Cancer Inst. 2011 Feb 2;103(3):250-63
pubmed: 21191117
Diabetes. 1998 Oct;47(10):1643-9
pubmed: 9753305
Bioessays. 2009 Apr;31(4):422-34
pubmed: 19274663
Cancer Epidemiol Biomarkers Prev. 2010 Jun;19(6):1532-44
pubmed: 20501755
Cytokine Growth Factor Rev. 2005 Aug-Oct;16(4-5):407-20
pubmed: 15886048